

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

BEDNARSKI *et al.*

Application No. 10/681,855

Filed: October 7, 2003

For: X-NITRO COMPOUNDS,
PHARMACEUTICAL COMPOSITIONS
THEREOF AND USES THEREOF

Examiner: ANDERSON, James D.

Art Unit: 1614 Conf. No.: 7135

CERTIFICATE OF ELECTRONIC TRANSMISSION
UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, including listed enclosures, is being electronically transmitted to the United States Patent and Trademark Office in accordance with 37 C.F.R. 1.6(a)(4) on:

Dated:

March 20, 2008

Signed:

Jennifer C. Black
Jennifer C. Black

DECLARATION UNDER 37 CFR 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Richard F. Trecartin, declare that:

1. I am the attorney of record for the above referenced application.
2. I am also the attorney of record for U.S. Provisional Application No. 60/890,167, which is attached hereto.
3. The Examples on pages 32-34 and 38-42 of the '167 Application disclose experiments with ABDNAZ.
4. All statements herein made of my own knowledge are true, and statements made on information or belief are believed to be true and correct.

5. I have been warned that willful false statements and the like are punishable by fine or imprisonment or both (18 USC 1001), and may jeopardize the validity of the patent application or any patent issuing thereon.

Date: March 20, 2008 

Richard F. Trecartin, Reg. No. 31,801



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
60/890,167	02/15/2007		100	067425-5004-Prov		

CONFIRMATION NO. 6546

67374
MORGAN, LEWIS & BOCKIUS, LLP
ONE MARKET SPEAR STREET TOWER
SAN FRANCISCO, CA 94105

FILING RECEIPT

Date Mailed: 03/13/2007

Receipt is acknowledged of this provisional Patent Application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lynn M. Oehler, Los Altos, CA;
Susan Knox, Stanford, CA;
Louis Cannizzo, Ogden, UT;
Kirstin Warner, Ogden, UT;
Robert Wardle, Ogden, UT;
Stephen Valarde, North Ogden, UT;
Shoucheng Ning, Palo Alto, CA;

Power of Attorney:
Richard Trecartin--31801

If Required, Foreign Filing License Granted: 03/12/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is
US60/890,167

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND
USES THEREOF

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not** result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of

Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PROVISIONAL APPLICATION FOR PATENT COVER SHEET - Page 1 of 2

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. _____

INVENTOR(S)		
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)
Lynn M.	Oehler	Los Altos, California
Susan	Knox	Stanford, California
Louis	Cannizzo	Ogden, Utah
Kirstin	Warner	Ogden, Utah
Robert	Wardle	Ogden, Utah

Additional inventors are being named on the _____ 1 _____ separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max):

CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF

Direct all correspondence to: **CORRESPONDENCE ADDRESS**

☒ The address corresponding to Customer Number: 67374

OR

☐ Firm or Individual Name

Address

City	State	Zip
Country	Telephone	Email

ENCLOSED APPLICATION PARTS (check all that apply)

☐ Application Data Sheet. See 37 CFR 1.76

☒ Drawing(s) Number of Sheets 8

☒ Specification (e.g. description of the invention) Number of Pages 47

☐ CD(s). Number of CDs _____

☐ Other (specify) _____

Fees Due: Filing Fee of \$200 (\$100 for small entity). If the specification and drawings exceed 100 sheets of paper, an application size fee is also due, which is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

METHOD OF PAYMENT OF THE FILING FEE AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.

☐ A check or money order is enclosed to cover the filing fee and application size fee (if applicable).

☐ Payment by credit card. Form PTO-2038 is attached

☒ The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit

Account Number: 50-0310 A duplicative copy of this form is enclosed for fee processing.

TOTAL FEE AMOUNT (\$) 100.00

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Provisional Application Cover Sheet
067425-5004-US-Prov
Inventors Cont. from page 1

Given Name	Surname	Residence
Stephen	VALARDE	North Ogden, Utah
Shoucheng	NING	Palo Alto, California

PROVISIONAL APPLICATION COVER SHEET
Page 2 of 2

PTO/SB/16 (02-07)

Approved for use through 02/28/2007. OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No.




Yes, the name of the U.S. Government agency and the Government contract number are: _____

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

SIGNATURE /



Date February 15, 2007

TYPED or PRINTED NAME Richard F. Trecairn

REGISTRATION NO. 31,801
(if appropriate)

TELEPHONE 415-442-1668

Docket Number: 067425-5004-Prov 1

CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF

FIELD OF THE INVENTION

[001] The present invention relates generally to pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and pharmaceutical compositions thereof to treat or prevent diseases characterized by abnormal cell proliferation such as cancer.

BACKGROUND OF THE INVENTION

[002] Abnormal cell proliferation is a characteristic symptom of cancer. Further, abnormal cell proliferation has been implicated in numerous other diseases (*e.g.*, cardiovascular diseases, inflammatory diseases such as rheumatoid arthritis, diabetic retinopathy, *etc.*). Although many methods for treating or preventing aberrant cell proliferation have been developed, a significant problem with most existing therapies is selectively distinguishing between normal and abnormal cell proliferation.

[003] Radiotherapy is one promising approach to selectively targeting abnormal cell proliferation. A number of different radiosensitizers have been described in the art and include thiols, nitroimidazoles and metal texaphyrin compounds (See *e.g.*, Rosenthal *et al.*, *Clin. Cancer. Res.*, 1999, 739). Significant problems with existing radiosensitization approaches are (1) the formation of toxic byproducts derived from the radiosensitizers, which has limited their usefulness in cancer therapy; and (2) achieving sufficiently high density of free radicals to be efficacious under dose limiting toxicity.


[004] Another popular approach to selectively targeting abnormal cell proliferation, is treatment with bioreductive compounds, which are selectively activated in a reducing environment. Since many cancers typically contain regions of low oxygen tension (*i.e.*, hypoxia), compounds with low redox potentials (*i.e.*, bioreductive compounds) may be selectively activated in the reducing environment of tumor cells without external activation.

[005] Accordingly, new compounds are required to fully explore treating or preventing abnormal cell proliferation. These new compounds may have radiotherapeutic activity or bioreductive activity. Such compounds may be effective in treating or preventing various diseases associated with abnormal cell proliferation such as cancer without forming toxic byproducts.

SUMMARY OF THE INVENTION

[006] The present invention satisfies this and other needs by providing cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds or pharmaceutical compositions thereof to treat or prevent diseases associated with abnormal cell proliferation.

[007] In a first aspect, a compound of structural Formula (I):



(I)

[008] or salts, solvates or hydrates thereof is provided wherein:

[009] R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

[0010] each R^5 and R^6 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

o is 0, 1, 2, 3 or 4;

[0011] R^7 is substituted alkyl, substituted arylalkyl, substituted heteroalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl;

[0012] provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are nitro.

[0013] In a second aspect, methods for treating or preventing diseases or disorders characterized by abnormal cell proliferation are provided. The methods generally involve administering to a patient in need of such treatment or prevention a therapeutically effective amount of a cyclic nitro compound or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof.

[0014] In a third aspect, pharmaceutical compositions of cyclic nitro compounds are provided. The pharmaceutical compositions generally comprise one or more cyclic nitro compounds, pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof and a pharmaceutically acceptable vehicle. The choice of vehicle will depend upon, among other factors, the desired mode of administration.

[0015] In a fourth aspect, pharmaceutical compositions for treating or preventing diseases or disorders characterized by abnormal cell proliferation are provided. The methods generally involve administering to a patient in need of such treatment or prevention a therapeutically effective amount of a pharmaceutical composition comprising a cyclic nitro compound or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof and a pharmaceutically acceptable vehicle.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 illustrates the dose and cell line dependency of ROS production in tumor cells in the presence of ABDNAZ;

[0017] Figure 2 illustrates ROS production in HT29 tumor cells in the presence of irradiated ABDNAZ;

[0018] Figure 3 illustrates ROS production in SCC VII tumor cells in the presence of irradiated ABDNAZ;

[0019] Figure 4 illustrates inhibition of proliferation of bcl-2 and vector transfected HL60 cells by ABDNAZ;

[0020] Figure 5 illustrates induction of apoptosis of bcl-2 and vector transfected HL60 cells by ABDNAZ;

[0021] Figure 6 illustrates the apoptosis and cell cycle profile of HL60 neo cells after exposure to ABDNAZ;

[0022] Figure 7 illustrates the apoptosis and cell cycle profile of HL60 bcl-2 cells after exposure to ABDNAZ; and

[0023] Figure 8 illustrates the inhibition of bcl-2 expression in HL 60 cells.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Definitions

[0024] “Alkyl” by itself or as part of another substituent refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, *etc.*; and the like.

[0025] The term “alkyl” is specifically intended to include groups having any degree or level of saturation, *i.e.*, groups having exclusively single carbon-carbon bonds, groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds and groups having mixtures of single, double and triple carbon-carbon bonds. Where a specific level of saturation is intended, the expressions “alkanyl,” “alkenyl,” and “alkynyl” are used. In some embodiments, an alkyl group comprises from 1 to 20 carbon atoms. In other embodiments, an alkyl group comprises 1 to 10 carbon atoms. In still other embodiments an alkyl group comprises from 1 to 6 carbon atoms.

[0026] “Alkanyl” by itself or as part of another substituent refers to a saturated branched, straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, *etc.*; butanyls such as butan-1-yl, butan-2-yl (*sec*-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (*t*-butyl), cyclobutan-1-yl, *etc.*; and the like.

[0027] “Alkenyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene. The group may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, *etc.*; and the like.

[0028] “Alkynyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not

limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, *etc.*; and the like.

[0029] “Acyl” by itself or as part of another substituent refers to a radical $-C(O)R^{30}$, where R^{30} is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl as defined herein. Representative examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

[0030] “Alkoxy carbonyl” by itself or as part of another substituent refers to a radical $-C(O)OR^{31}$ where R^{31} represents an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, cyclohexyloxycarbonyl and the like.

[0031] “Aryl” by itself or as part of another substituent refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. In some embodiments, an aryl group comprises from 6 to 20 carbon atoms. In other embodiments, an aryl group comprises from between 6 to 12 carbon atoms.

[0032] “Arylalkyl” by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl,

naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. In some embodiments, an arylalkyl group is (C₆-C₃₀) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₁₀) and the aryl moiety is (C₆-C₂₀). In other embodiments, an arylalkyl group is (C₆-C₂₀) arylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₁-C₈) and the aryl moiety is (C₆-C₁₂).

[0033] “Heteroalkyl, Heteroalkanyl, Heteroalkenyl and Heteroalkynyl” by themselves or as part of another substituent refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatomic groups. Typical heteroatomic groups which can be included in these groups include, but are not limited to, -O-, -S-, -O-O-, -S-S-, -O-S-, -NR³⁴R³⁵-, =N-N=, -N=N-, -N=N-NR³⁶R³⁷-, -PR³⁸-, -P(O)₂-, -POR³⁹-, -O-P(O)₂-, -SO-, -SO₂-, -SnR⁴⁰R⁴¹- and the like, where R³⁴, R³⁵, R³⁶, R³⁷, R³⁸, R³⁹, R⁴⁰ and R⁴¹ are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

[0034] “Heteroaryl” by itself or as part of another substituent refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arindole, carbazole, β-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In some embodiments, the heteroaryl group is between 5-20 membered heteroaryl. In other embodiments, the heteroaryl group is between 5-10 membered heteroaryl.

In some embodiments, heteroaryl groups include those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.

[0035] “Heteroarylalkyl” by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl and/or heteroarylalkynyl is used. In some embodiments, the heteroarylalkyl group is a 6-30 membered heteroarylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-10 membered and the heteroaryl moiety is a 5-20-membered heteroaryl. In other embodiments, the heteroarylalkyl group is a 6-20 membered heteroarylalkyl, *e.g.*, the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-8 membered and the heteroaryl moiety is a 5-12-membered heteroaryl.

[0036] “Parent Aromatic Ring System” by itself or as part of another substituent, refers to an unsaturated cyclic or polycyclic ring system having a conjugated π electron system. Specifically included within the definition of “parent aromatic ring system” are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, *etc.* Typical parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *as*-indacene, *s*-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like.

[0037] “Parent Heteroaromatic Ring System” by itself or as part of another substituent, refers to a parent aromatic ring system in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the

same or different heteroatom. Typical heteroatoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, *etc.* Specifically included within the definition of “parent heteroaromatic ring systems” are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, arsindole, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, *etc.* Typical parent heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, β -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.

[0038] “Pharmaceutically acceptable salt” refers to a salt of a O-nitro compound, which is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, *t*-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by an ammonium ion, a metal ion, *e.g.*, a alkali metal ion (*e.g.*, sodium or potassium), an alkaline earth ion (*e.g.*, calcium or magnesium), or

an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, piperidine, dimethylamine, diethylamine and the like. Also included are salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like.

[0039] “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a O-nitro compound is administered.

[0040] “Patient” includes humans and other mammals.

[0041] “Phosphonyl” by itself or as part of another substituent refers to a radical $-P(O)(OR^{32})_2$, where each R^{32} is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl as defined herein.

[0042] “Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (*i.e.*, causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).

[0043] “Substituted” refers to a group in which one or more hydrogen atoms are independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, $-M$, $-R^{60}$, $-O^-$, $=O$, $-OR^{60}$, $-SR^{60}$, $-S^-$, $=S$, $-NR^{60}R^{61}$, $=NR^{60}$, $-CF_3$, $-CN$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $-ONO_2$, $=N_2$, $-N_3$, $-S(O)_2O^-$, $-S(O)_2OH$, $-S(O)_2R^{60}$, $-OS(O)_2O^-$, $-OS(O)_2R^{60}$, $-P(O)(O^-)_2$, $-P(O)(OR^{60})(O^-)$, $-OP(O)(OR^{60})(OR^{61})$, $-C(O)R^{60}$, $-C(S)R^{60}$, $-C(O)OR^{60}$, $-C(O)NR^{60}R^{61}$, $-C(O)O^-$, $-C(S)OR^{60}$, $-NR^{62}C(O)NR^{60}R^{61}$, $-NR^{62}C(S)NR^{60}R^{61}$, $-NR^{62}C(NR^{63})NR^{60}R^{61}$ and $-C(NR^{62})NR^{60}R^{61}$ where M is independently a halogen; R^{60} , R^{61} , R^{62} and R^{63} are independently hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R^{60} and R^{61} together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl

ring; and R^{64} and R^{65} are independently hydrogen, alkyl, substituted alkyl, aryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or optionally R^{64} and R^{65} together with the nitrogen atom to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring. In some embodiments, substituents include $-M$, $-R^{60}$, $=O$, $-OR^{60}$, $-SR^{60}$, $-S^+$, $=S$, $-NR^{60}R^{61}$, $=NR^{60}$, $-CF_3$, $-CN$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $-ONO_2$, $=N_2$, $-N_3$, $-S(O)_2R^{60}$, $-OS(O)_2O^+$, $-OS(O)_2R^{60}$, $-P(O)(O^-)_2$, $-P(O)(OR^{60})(O^-)$, $-OP(O)(OR^{60})(OR^{61})$, $-C(O)R^{60}$, $-C(S)R^{60}$, $-C(O)OR^{60}$, $-C(O)NR^{60}R^{61}$, $-C(O)O^-$, $-NR^{62}C(O)NR^{60}R^{61}$, where R^{60} , R^{61} and R^{62} are as defined above. In other embodiments, substituents include $-M$, $-R^{60}$, $=O$, $-OR^{60}$, $-SR^{60}$, $-NR^{60}R^{61}$, $-CF_3$, $-CN$, $-NO_2$, $-ONO_2$, $-S(O)_2R^{60}$, $-P(O)(OR^{60})(O^-)$, $-OP(O)(OR^{60})(OR^{61})$, $-C(O)R^{60}$, $-C(O)OR^{60}$, $-C(O)NR^{60}R^{61}$ and $-C(O)O^-$ where R^{60} , R^{61} and R^{62} are as defined above. In still other embodiments, substituents include $-M$, $-R^{60}$, $=O$, $-OR^{60}$, $-SR^{60}$, $-NR^{60}R^{61}$, $-CF_3$, $-CN$, $-NO_2$, $-ONO_2$, $-S(O)_2R^{60}$, $-OP(O)(OR^{60})(OR^{61})$, $-C(O)R^{60}$, $-C(O)OR^{60}$ and $-C(O)O^-$, where R^{60} , R^{61} and R^{62} are as defined above.

[0044] “Sulfonyl” by itself or as part of another substituent refers to a radical $-S(O)_2R^{33}$, where each R^{33} is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl as defined herein.

[0045] “Treating” or “treatment” of any disease or disorder refers, in some embodiments, to ameliorating the disease or disorder (*i.e.*, arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In other embodiments “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet other embodiments, “treating” or “treatment” refers to inhibiting the disease or disorder, either physically, (*e.g.*, stabilization or eradication of a discernible symptom), physiologically, (*e.g.*, stabilization or eradication of a physical parameter) or both. In still other embodiments, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

[0046] "Therapeutically effective amount" means the amount of a compound that, when administered to a patient for treating or preventing a disease, is sufficient to effect such treatment or prevention of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, *etc.*, of the patient to be treated.

[0047] Reference will now be made in detail to embodiments of the invention. While the invention will be described in conjunction with these embodiments, it will be understood that it is not intended to limit the invention to those preferred embodiments. To the contrary, it is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims.

[0048] "Pharmaceutically acceptable salt" refers to a salt of a cyclic nitro compound, which is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, *t*-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by an ammonium ion, a metal ion, *e.g.*, a alkali metal ion (*e.g.*, sodium or potassium), an alkaline earth ion (*e.g.*, calcium or magnesium), or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, piperidine, dimethylamine, diethylamine and the like. Also included are salts of amino acids

such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like.

[0049] “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a cyclic nitro compound is administered.

[0050] “Patient” includes humans and other mammals.

[0051] “Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (*i.e.*, causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).

[0052] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (*i.e.*, arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet another embodiment, “treating” or “treatment” refers to inhibiting the disease or disorder, either physically, (*e.g.*, stabilization or eradication of a discernible symptom), physiologically, (*e.g.*, stabilization or eradication of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

[0053] “Therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating or preventing a disease, is sufficient to effect such treatment or prevention of the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, *etc.*, of the patient to be treated.

[0054] Reference will now be made in detail to embodiments of the invention. While the invention will be described in conjunction with these embodiments, it will be understood that it is not intended to limit the invention to those preferred embodiments. To the contrary, it is intended to cover alternatives, modifications,

and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims.

Cyclic Nitro Compounds and Their Use To Treat or Prevent Abnormal Cell Proliferation

[0055] The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds or pharmaceutical compositions thereof to treat or prevent diseases associated with abnormal cell proliferation.

[0056] The methods generally involve administering to a patient in need of such treatment or prevention a therapeutically effective amount of a cyclic nitro compound or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof. In one embodiment, the cyclic nitro compound is intracellularly activated by the reducing environment of a tumor cell. In another embodiment, the patient is irradiated to activate the cyclic nitro compound. Without wishing to be bound by theory, irradiation or reduction of cyclic nitro compounds may lead to formation of free radicals that subsequently prevent cell replication and kill cells, presumably by interfering with DNA replication and/or reacting with cell membranes. However, other mechanisms, presently unknown, may account for the efficacy of cyclic nitro compounds in treating or preventing abnormal cell proliferation.

[0057] Accordingly, in some embodiments, the cyclic nitro compounds of the present invention may be activated by both intracellular reduction and external irradiation. In these embodiments, a synergistic or additive effect may be observed.

[0058] Cyclic nitro compounds are generally organic compounds substituted with one or more nitro groups (*i.e.*, nitro compounds) but also include nitrate salts (*e.g.*, ammonium dinitride, aluminum trinitride, *etc.*). Typically, cyclic nitro compounds have a high enthalpy of formation (*i.e.*, decomposition of cyclic nitro compounds releases a high amount of energy). In some embodiments, cyclic nitro compounds have an enthalpy of formation that varies between about 5 kcal/mole and about 150 kcal/mole, more preferably, between about 10 kcal/mole and about


110 kcal/mole. The enthalpy of formation of nitro compounds may be readily calculated by methods known to the skilled artisan. Accordingly, cyclic nitro compounds include those nitro compounds that decompose with explosive force upon activation. Such compounds may be readily identified by those of skill in the art by calculation of the enthalpy of formation.

[0059] Cyclic nitro compounds may also be reduced at low reduction potentials. cyclic voltametry demonstrates that electron transfer to cyclic nitro compounds occurs between about -0.1 volts and about -1.0 volts using standard electrodes (*e.g.*, mercury or carbon cathode and platinum anode) and electrolyte solutions.

[0060] In some embodiments, cyclic nitro compounds contain a high density of nitro groups (*i.e.*, the nitro groups represent a significant fraction of the overall mass of the compound). In other embodiments, cyclic nitro compounds contain two nitro groups. In still other embodiments, cyclic nitro compounds contain three nitro groups. In still other embodiments, cyclic nitro compounds contain three or more nitro groups. In still other embodiments, a cyclic nitro compound contains six nitro groups.

[0061] In some embodiments, the cyclic nitro compound is a nitrocarbon which has a ratio of nitro groups to carbon atoms of 1:1. In other embodiments, the cyclic nitro compound is a nitrocarbon which has a ratio of nitro groups to carbon atoms of 1:2.

[0062] In some embodiments, a compound of structural Formula (I):



(I)

[0063] or salts, solvates or hydrates thereof is provided wherein:

[0064] R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl,

substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

[0065] each R^5 and R^6 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

o is 0, 1, 2, 3 or 4;

[0066] R^7 is substituted alkyl, substituted arylalkyl, substituted heteroalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl;

[0067] provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are nitro.


[0068] In some embodiments, at least two of R^1 , R^2 , R^3 , R^4 , R^5 or R^6 are nitro. In other embodiments, R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro and each R^5 and R^6 are each independently, hydrogen, alkyl or nitro. In still other embodiments, R^7 is substituted alkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl. In still other embodiments, R^7 is alkyl, acyl, alkoxycarbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl. In still other embodiments, R^3 and R^4 are nitro.

[0069] In some embodiments, R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is substituted alkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl. In other embodiments, R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is alkyl, acyl, alkoxycarbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl. In still other

embodiments, R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro, R^7 is substituted alkyl, substituted acyl, substituted alkoxy carbonyl, substituted phosphonyl or substituted sulfonyl. In still other embodiments, R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro, R^7 is alkyl, acyl, alkoxy carbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl. In some of any of the above embodiments, o is 1.


[0070] In some embodiments, R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, R^5 and R^6 are each independently, hydrogen, alkyl or nitro, R^7 is alkyl or acyl substituted with one or more halogen or $-CF_3$ and o is 1. In other embodiments, R^1 and R^2 are hydrogen, R^3 and R^4 are nitro, R^5 and R^6 are hydrogen, R^7 is alkyl or acyl substituted with one or more halogen or $-CF_3$ and o is 1.

[0071] In some embodiments, the cyclic nitro compound has the structure:




[0072] wherein each X is independently -F, -Cl, -Br, -I or $-OS(O)_2R^8$ where R^8 is methyl, CF_3 , phenyl or tolyl and each p is independently 1, 2, 3, or 4.

[0073] In other embodiments, the cyclic nitro compound has the structure:



[0074] wherein each X is independently -F, -Cl, -Br, -I or $-OS(O)_2R^8$ where R^8 is methyl, CF_3 , phenyl or tolyl. In some specific embodiments, the cyclic nitro compound has the structure:



[0075] commonly referred to as ABDNAZ.

[0076] Cyclic nitro compounds may exist in several tautomeric forms and mixtures thereof. Cyclic nitro compounds may also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into cyclic nitro compounds include, but are not limited to, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O and ^{17}O . Cyclic nitro compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms or a N-oxides. In general, hydrated and solvated forms are within the scope of the present invention. Certain cyclic nitro compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0077] Cyclic nitro compounds may be activated by intracellular reduction. In some embodiments, cyclic nitro compounds are activated by intracellular reduction in hypoxic tumor cells, secondary to elevated glutathione levels (high GSH:GSSG (*i.e.*, glutathione to glutathione disulfide ratios)) and possibly high levels of other antioxidant enzymes in many tumor cells and/or a median tumor cell pO_2 of less than about 10 mm Hg.

[0078] Cyclic nitro compounds may also be activated by application of external energy. Methods useful for decomposing cyclic nitro compounds include, but are not limited to, irradiation (*e.g.*, with x-rays, visible light, infrared irradiation) ultrasound (*e.g.* focused ultrasound), electrochemical reduction, heating, co-administration of free radical initiators (*e.g.*, thiols), *etc.* In some embodiments, a cyclic nitro compound is activated by photon irradiation of the patient. In some embodiments, the patient's tumor is irradiated using a linear accelerator at a dose rate of about 100 cGy/min. The patient may also be treated

with electron beam therapy, interoperative radiation therapy, stereostatic radiosurgery and high or low dose brachytherapy.

[0079] In some situations the entire patient may be irradiated. In some embodiments, a portion of the patient is irradiated so that only cyclic nitro compound localized in the irradiated portion (*e.g.*, tumor region) of the patient is activated. Preferably, the portion of the patient which is irradiated is the site of abnormal cell proliferation.

[0080] Cyclic nitro compounds may be obtained *via* conventional synthetic methods described in the art or are commercially available, *e.g.*, from ATK Thiokol, Salt Lake City, UT. Starting materials useful for preparing cyclic nitro compounds and intermediates thereof are commercially available or can be prepared by well-known synthetic methods. Other methods for synthesis of the cyclic nitro compounds described herein and/or starting materials are either described in the art or will be readily apparent to the skilled artisan.

[0081] In accordance with the invention, a cyclic nitro compound or a pharmaceutical composition thereof is administered to a patient, preferably a human, suffering from a disease characterized by abnormal cell proliferation. The cyclic nitro compound and pharmaceutical compositions thereof may be used to treat or prevent diseases characterized by abnormal cell proliferation.

[0082] Diseases characterized by abnormal cell proliferation include, but are not limited to, cancer (*e.g.*, any vascularized tumor, preferably, a solid tumor, including but not limited to, carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, neuroblastomas, sarcomas (*e.g.*, angiosarcomas, chondrosarcomas), diabetes, cardiovascular diseases (*e.g.*, arteriosclerosis), inflammatory diseases (*e.g.*, arthritis, diabetic retinopathy, rheumatoid arthritis, neovascular glaucoma and psoriasis) and autoimmune diseases.

[0083] In other embodiments, cyclic nitro compounds may be used for *in-vitro* sterilization. Biological solutions may be treated with cyclic nitro compounds, which are toxic to pathogenic bacteria, viruses and cells. This process can also be catalyzed by the application of external energy such as light and heat.

[0084] Further, in certain embodiments, a cyclic nitro compound and/or pharmaceutical compositions thereof are administered to a patient, preferably a human, as a preventative measure against various diseases or disorders characterized by abnormal cell proliferation. Thus, cyclic nitro compounds and/or pharmaceutical compositions thereof may be administered as a preventative measure to a patient having a predisposition for a disease characterized by abnormal cell proliferation. Accordingly, cyclic nitro compounds and/or pharmaceutical compositions thereof may be used for the prevention of one disease or disorder and concurrently treating another (*e.g.*, preventing arthritis while treating cancer).

Therapeutic/Prophylactic Administration

[0085] Cyclic nitro compounds and/or pharmaceutical compositions thereof may be advantageously used in human medicine. As previously described in Section 5.2 *supra*, cyclic nitro compounds and/or pharmaceutical compositions thereof are useful for the treatment or prevention of various diseases or disorders such as those listed above.

[0086] When used to treat or prevent the above disease or disorders, cyclic nitro compounds and/or pharmaceutical compositions thereof may be administered or applied singly, or in combination with other agents. Cyclic nitro compounds and/or pharmaceutical compositions thereof may also be administered or applied singly, or in combination with other pharmaceutically active agents (*e.g.*, other anti-cancer agents, other arthritis agents, *etc.*), including other cyclic nitro compounds and/or pharmaceutical compositions thereof.

[0087] The current invention provides methods of treatment and prophylaxis by administration to a patient of a therapeutically effective amount of a cyclic nitro compound and/or pharmaceutical composition thereof. The patient is preferably, a mammal and most preferably, is a human.

[0088] Cyclic nitro compounds and/or pharmaceutical compositions thereof may be administered orally. Cyclic nitro compounds and/or pharmaceutical compositions thereof may also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, *etc.*). Administration can be systemic or local. Various delivery systems are known, (*e.g.*, encapsulation in liposomes, microparticles, microcapsules, capsules, *etc.*) that can be used to administer a cyclic nitro compound and/or pharmaceutical composition thereof. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes or skin. The mode of administration is left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition. In most instances, administration will result in the release of cyclic nitro compounds and/or pharmaceutical compositions thereof into the bloodstream.

[0089] In specific embodiments, it may be desirable to administer one or more cyclic nitro compounds and/or pharmaceutical compositions thereof locally to the area in need of treatment. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of the disease or disorder.

[0090] In certain embodiments, it may be desirable to introduce one or more cyclic nitro compounds and/or pharmaceutical compositions thereof into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

[0091] Cyclic nitro compounds and/or pharmaceutical compositions thereof may also be administered directly to the lung by inhalation. For administration by inhalation, cyclic nitro compounds and/or pharmaceutical composition thereof may be conveniently delivered to the lung by a number of different devices. For example, a Metered Dose Inhaler ("MDI"), which utilizes canisters that contain a suitable low boiling propellant, (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or any other suitable gas) may be used to deliver cyclic nitro compounds and/or pharmaceutical compositions thereof directly to the lung.

[0092] Alternatively, a Dry Powder Inhaler ("DPI") device may be used to administer a cyclic nitro compound and/or pharmaceutical composition thereof to the lung. DPI devices typically use a mechanism such as a burst of gas to create a cloud of dry powder inside a container, which may then be inhaled by the patient and are well known in the art. A popular variation is the multiple dose DPI ("MDDPI") system, which allows for the delivery of more than one therapeutic dose. MDDPI devices are commercially available from a number of pharmaceutical companies e.g., Schering Plough, Madison, NJ). For example, capsules and cartridges of gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a cyclic nitro compound and/or pharmaceutical composition thereof and a suitable powder base such as lactose or starch for these systems.

[0093] Another type of device that may be used to deliver a cyclic nitro compound and/or pharmaceutical composition thereof to the lung is a liquid spray device supplied, for example, by Aradigm Corporation, Hayward, CA. Liquid spray systems use extremely small nozzle holes to aerosolize liquid drug formulations that may then be directly inhaled into the lung.

[0094] In some embodiments, a nebulizer is used to deliver a cyclic nitro compound and/or pharmaceutical composition thereof to the lung. Nebulizers create aerosols from liquid drug formulations by using, for example, ultrasonic energy to form fine particles that may be readily inhaled (see e.g., Verschoyle *et al.*, *British J. Cancer*, 1999, 80, Suppl. 2, 96). Examples of nebulizers include devices supplied by Sheffield Pharmaceuticals, St. Louis, MO. (Armer *et al.*,

United States Patent No. 5,954,047; van der Linden *et al.*, United States Patent No. 5,950,619; van der Linden *et al.*, United States Patent No. 5,970,974) and Batelle Pulmonary Therapeutics, Columbus, OH).

[0095] In other embodiments, an electrohydrodynamic ("EHD") aerosol device is used to deliver a cyclic nitro compound and/or pharmaceutical composition thereof to the lung of a patient. EHD aerosol devices use electrical energy to aerosolize liquid drug solutions or suspensions (see *e.g.*, Noakes *et al.*, United States Patent No. 4,765,539). The electrochemical properties of the formulation may be important parameters to optimize when delivering a cyclic nitro compound and/or pharmaceutical composition thereof to the lung with an EHD aerosol device and such optimization is routinely performed by one of skill in the art. EHD aerosol devices may more efficiently deliver drugs to the lung than existing pulmonary delivery technologies.

[0096] In some embodiments, a cyclic nitro compound and/or pharmaceutical compositions thereof can be delivered in a vesicle, in particular a liposome (*e.g.*, Langer, 1990, *Science*, 249:1527-1533; Treut *et al.*, in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, pp.353-365 (1989)).

[0097] In some embodiments, a cyclic nitro compound and/or pharmaceutical compositions thereof can be delivered *via* sustained release systems, preferably oral sustained release systems. In other embodiments, a pump may be used (*e.g.*, Langer, *supra*, Sefton, 1987, *CRC Crit. Rev Biomed. Eng.* 14:201; Saudek *et al.*, 1989, *N. Engl. J Med.* 321:574).

[0098] In some embodiments, polymeric materials can be used (*e.g.*, "Medical Applications of Controlled Release," Langer and Wise (eds.), CRC Press, Boca Raton, Florida (1974); "Controlled Drug Bioavailability," Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger *et al.*, 1983, *J Macromol. Sci. Rev. Macromol Chem.* 23:61; Levy *et al.*, 1985, *Science* 228: 190; During *et al.*, 1989, *Ann. Neurol.* 25:351; Howard *et al.*, 1989, *J. Neurosurg.* 71:105).

[0099] In other embodiments, polymeric materials are used for oral sustained release delivery. Polymers include, but are not limited to, sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose (most preferred, hydroxypropyl methylcellulose). Other cellulose ethers have been described (Alderman, *Int. J. Pharm. Tech. & Prod. Mfr.* 1984, 5(3) 1-9). Factors affecting drug release are well known to the skilled artisan and have been described in the art (Bamba *et al.*, *Int. J. Pharm.* 1979, 2, 307).

[00100] In other embodiments, enteric-coated preparations can be used for oral sustained release administration. Coating materials include polymers with a pH-dependent solubility (*i.e.*, pH-controlled release), polymers with a slow or pH-dependent rate of swelling, dissolution or erosion (*i.e.*, time-controlled release), polymers that are degraded by enzymes (*i.e.*, enzyme-controlled release) and polymers that form firm layers that are destroyed by an increase in pressure (*i.e.*, pressure-controlled release).

[00101] In other embodiments, osmotic delivery systems are used for oral sustained release administration (Verma *et al.*, *Drug Dev. Ind. Pharm.*, 2000, 26:695-708). In some embodiments, OROSTM osmotic devices are used for oral sustained release delivery devices (Theeuwes *et al.*, United States Patent No. 3,845,770; Theeuwes *et al.*, United States Patent No. 3,916,899).

[00102] In yet other embodiments, a controlled-release system can be placed in proximity of the target of the cyclic nitro compound and/or pharmaceutical composition, thus requiring only a fraction of the systemic dose (*e.g.*, Goodson, in "Medical Applications of Controlled Release," *supra*, vol. 2, pp. 115-138 (1984)). Other controlled-release systems previously may also be used (Langer, 1990, *Science* 249:1527-1533).

Pharmaceutical Compositions

[00103] The present pharmaceutical compositions typically contain a therapeutically effective amount of one or cyclic nitro compounds, preferably, in purified form, together with a suitable amount of a pharmaceutically acceptable vehicle, so as to provide the form for proper administration to a patient. When administered to a patient, the cyclic nitro compound and pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the cyclic nitro compound is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The present pharmaceutical compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used.

[00104] Pharmaceutical compositions comprising a cyclic nitro compound may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries, which facilitate processing of compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[00105] The present pharmaceutical compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (*e.g.*, Grosswald *et al.*, United States Patent No. 5,698,155). A general discussion of the preparation of pharmaceutical compositions may be found in Remington, "The Science and Practice of Pharmacy," 19th Edition.

[00106] For topical administration a cyclic nitro compound may be formulated as solutions, gels, ointments, creams, suspensions, *etc.* as is well-known in the art.

[00107] Systemic formulations include those designed for administration by injection, *e.g.*, subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration. Systemic formulations may be made in combination with a further active agent that improves mucociliary clearance of airway mucus or reduces mucous viscosity. These active agents include, but are not limited to, sodium channel blockers, antibiotics, N-acetyl cysteine, homocysteine and phospholipids.

[00108] In a preferred embodiment, cyclic nitro compounds are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, cyclic nitro compounds are solutions in sterile isotonic aqueous buffer for intravenous administration. For injection, cyclic nitro compounds may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. When necessary, the pharmaceutical compositions may also include a solubilizing agent. Pharmaceutical compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. When the cyclic nitro compounds are administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. When the cyclic nitro compound is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[00109] For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[00110] Pharmaceutical compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered pharmaceutical compositions may contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry coloring agents and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, when in tablet or pill form, the pharmaceutical compositions may be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, *etc.* Such vehicles are preferably of pharmaceutical grade.

[00111] For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, saline, alkylenglycols (*e.g.*, propylene glycol), polyalkylene glycols (*e.g.*, polyethylene glycol) oils, alcohols, slightly acidic buffers between pH 4 and pH 6 (*e.g.*, acetate, citrate, ascorbate at between about 5.0 mM to about 50.0 mM), *etc.* Additionally, flavoring agents, preservatives, coloring agents, bile salts, acylcarnitines and the like may be added.

[00112] For buccal administration, the pharmaceutical compositions may take the form of tablets, lozenges, *etc.* formulated in conventional manner.

[00113] Liquid drug formulations suitable for use with nebulizers and liquid spray devices and EHD aerosol devices typically include a cyclic nitro compound with a pharmaceutically acceptable vehicle. Preferably, the pharmaceutically acceptable vehicle is a liquid such as alcohol, water, polyethylene glycol or a perfluorocarbon. Optionally, another material may be added to alter the aerosol properties of the solution or suspension of compounds. Preferably, this material is liquid such as an alcohol, glycol, polyglycol or a fatty acid. Other methods of formulating liquid drug solutions or suspension suitable for use in aerosol devices are known to those of skill in the art (see, *e.g.*, Biesalski, United States Patent No. 5,112,598; Biesalski, United States Patent No. 5,556,611).

[00114] A cyclic nitro compound may also be formulated in rectal or vaginal pharmaceutical compositions such as suppositories or retention enemas. *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[00115] In addition to the formulations described previously, a cyclic nitro compound may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, a cyclic nitro compound may be formulated with suitable polymeric or hydrophobic materials (*e.g.*, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, such as a sparingly soluble salt.

[00116] When a cyclic nitro compound is acidic or basic, it may be included in any of the above-described formulations as the free acid or free base, a pharmaceutically acceptable salt, a solvate or hydrate. Pharmaceutically acceptable salts substantially retain the activity of the free acid or base, may be prepared by reaction with bases or acids and tend to be more soluble in aqueous and other protic solvents than the corresponding free acid or base form.

Doses

[00117] A cyclic nitro compound and/or pharmaceutical composition thereof, will generally be used in an amount effective to achieve the intended purpose. For

use to treat or prevent the above diseases or disorders the cyclic nitro compound and/or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount.

[00118] The amount of a cyclic nitro compound and/or pharmaceutical composition thereof that will be effective in the treatment of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques known in the art. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The amount of a cyclic nitro compound and/or pharmaceutical composition thereof administered will, of course, be dependent on, among other factors, the subject being treated, the weight of the subject, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

[00119] For example, the dosage may be delivered in a pharmaceutical composition by a single administration, by multiple applications or controlled release. Dosing may be repeated intermittently, may be provided alone or in combination with other drugs and may continue as long as required for effective treatment of the disease state or disorder.

[00120] Suitable dosage ranges for oral administration are dependent on the efficiency of radiosensitization, but are generally about 0.001 mg to about 100 mg of the cyclic nitro compound per kg body weight. Dosage ranges may be readily determined by methods known to the artisan of ordinary skill.

[00121] Suitable dosage ranges for intravenous (i.v.) administration are about 0.01 mg to about 100 mg per kg/ body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 mg/kg body weight to about 1 mg/kg body weight. Suppositories generally contain about 0.01 milligram to about 50 milligrams of a cyclic nitro compound per kg/ body weight and comprise active ingredient in the range of about 0.5% to about 10% by weight. Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual or intracerebral administration are in the range of about 0.001 mg to about 200 mg per kg/ body weight. Effective doses may be

extrapolated from dose-response curves derived from *in vitro* or animal model test systems. Such animal models and systems are well-known in the art.

[00122] The cyclic nitro compounds are preferably assayed *in vitro* and *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. For example, *in vitro* assays can be used to determine whether administration of a specific cyclic nitro compound or a combination of cyclic nitro compounds is preferred. The cyclic nitro compound may also be demonstrated to be effective and safe using animal model systems.

[00123] Preferably, a therapeutically effective dose of a cyclic nitro compound and/or pharmaceutical composition thereof described herein will provide therapeutic benefit without causing substantial toxicity. Toxicity of cyclic nitro compounds and/or pharmaceutical compositions thereof may be determined using standard pharmaceutical procedures and may be readily ascertained by the skilled artisan. The dose ratio between toxic and therapeutic effect is the therapeutic index. A cyclic nitro compound and/or pharmaceutical composition thereof will preferably exhibit particularly high therapeutic indices in treating disease and disorders characterized by aberrant abnormal cell proliferation. The dosage of a cyclic nitro compound and/or pharmaceutical composition thereof described herein will preferably be within a range of circulating concentrations that include an effective dose with little or no toxicity.

Combination Therapy

[00124] In certain embodiments of the present invention, cyclic nitro compounds and/or pharmaceutical compositions thereof can be used in combination therapy with at least one other therapeutic agent. The cyclic nitro compound and/or pharmaceutical composition thereof and the therapeutic agent can act additively or, more preferably, synergistically. In one embodiment, a cyclic nitro compound and/or a pharmaceutical composition thereof is administered concurrently with the administration of another therapeutic agent. In another embodiment, a cyclic nitro compound and/or pharmaceutical composition thereof is administered prior or subsequent to administration of another therapeutic agent.

[00125] In particular, in one embodiment, cyclic nitro compounds and/or pharmaceutical compositions thereof can be used in combination therapy with other chemotherapeutic agents (*e.g.*, alkylating agents (*e.g.*, nitrogen mustards (*e.g.*, cyclophosphamide, ifosfamide, mechlorethamine, melphalen, chlorambucil, hexamethylmelamine, thiotepa), alkyl sulfonates (*e.g.*, busulfan), nitrosoureas, triazines)), antimetabolites (*e.g.*, folic acid analogs, pyrimidine analogs (*e.g.*, fluorouracil, floxuridine, cytosine arabinoside, *etc.*), purine analogs (*e.g.*, mercaptopurine, thioguanine, pentostatin, *etc.*), natural products (*e.g.*, vinblastine, vincristine, etoposide, tertiposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, mithramycin, mitomycin C, L-asparaginase, interferon alpha), platinum coordination complexes (*e.g.*, *cis*-platinum, carboplatin, *etc.*), apoptosis inducing agents, glutathione depleting agents or other agents that can alter the redox status of the cell. Those of skill in the art will appreciate that cyclic nitro compounds may also be used in concurrent combination therapy with both the chemotherapeutic agents listed above and radiotherapy.

Therapeutic Kits

[00126] The current invention also provides therapeutic kits comprising cyclic nitro compounds and/or pharmaceutical compositions thereof. The therapeutic kits may also contain other compounds (*e.g.*, chemotherapeutic agents, natural products, apoptosis-inducing agents, *etc.*) or pharmaceutical compositions thereof.

[00127] Therapeutic kits may have a single container which contains a cyclic nitro compound and/or pharmaceutical compositions thereof with or without other components (*e.g.*, other compounds or pharmaceutical compositions of these other compounds) or may have distinct container for each component. Preferably, therapeutic kits include a cyclic nitro compound and/or a pharmaceutical composition thereof packaged for use in combination with the co-administration of a second compound (preferably, a chemotherapeutic agent, a natural product, an apoptosis-inducing agent, *etc.*) or a pharmaceutical composition thereof. The components of the kit may be pre-complexed or each component may be in a separate distinct container prior to administration to a patient.

[00128] The components of the kit may be provided in one or more liquid solutions, preferably, an aqueous solution, more preferably, a sterile aqueous solution. The components of the kit may also be provided as solids, which may be converted into liquids by addition of suitable solvents, which are preferably provided in another distinct container.

[00129] The container of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any other means of enclosing a solid or liquid. Usually, when there is more than one component, the kit will contain a second vial or other container, which allows for separate dosing. The kit may also contain another container for a pharmaceutically acceptable liquid.

[00130] Preferably, a therapeutic kit will contain apparatus (*e.g.*, one or more needles, syringes, eye droppers, pipette, *etc.*), which enables administration of the components of the kit.

EXAMPLES

[00131] The invention is further defined by reference to the following examples, which describe in detail, preparation of compounds and methods for assaying for biological activity. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope.

Example 1: Production of ROS in Tumor

Cells by ABDNAZ and Irradiation

[00132] Human colon cancer cell line HT29 cells and murine squamous cell carcinoma cell line SCC VII cells were grown in 96-well plate overnight at 37°C and then a fluorescent probe 2'7'-dichlorofluorescein diacetate (DCFH-DA) was added at a concentration of 20 μ M for 1 hour and then washed out. ABDNAZ was added in the growth media at concentrations of 1 μ M, 10 μ M or 100 μ M. The green fluorescence was observed under a fluorescence microscope and measured using a microplate spectrofluorometer with an excitation at 488 nm and an emission at 525 nm. For cells that were treated with both ABDNAZ and

irradiation, the plates were irradiated immediately after addition of ABDNAZ using a ^{137}Cs source.

[00133] Figure 1 shows the production of reactive oxygen species (ROS) in HT29 cells and SCC VII cells after exposure to ABDNAZ. The production of ROS was dose, time and cell line dependent. The ROS production in HT29 cells was gradually increased over time and peaked at 24 hours. For SCC VII cells, the production of ROS was peaked 2 hours after addition of ABDNAZ, and the levels of ROS were significantly higher than that induced in HT29 cells.

[00134] Figures 2 and 3 illustrate the ROS production in HT29 cells and SCC VII cells treated with ABDNAZ and radiation. Combined treatment of ABDNAZ and radiation synergistically induced intracellular ROS generation in HT29 cells and SCC VII cells, as compared with each modality alone.

Example 2: Inhibition of Proliferation of HL60 cells by ABDNAZ

[00135] HL60 cell line which is an acute promyelocytic leukemia cell line was stably transfected with bcl-2 oncogene (HL60 bcl-2 cells). The HL60 neo cells were used as a control (HL60 neo). Cells were grown in RPMI1640 media in the presence of ABDNAZ at a concentration of 1 μM , 2 μM or 5 μM . The number of viable cells was counted daily for 10 days. The cell growth curves were shown in Figure 4 which demonstrates that ABDNAZ inhibited cell growth in a dose-dependent manner. A dose of 5 μM of ABDNAZ inhibited cell growth by > 95% and HL60 bcl-2 cells were as sensitive as neo cells to ABDNAZ.

Example 3: Induction of Apoptosis of HL 60 cells by ABDNAZ

[00136] Cells, prepared and grown as described in Example 2, *supra*, were collected at 8, 24, 48, and 72 hours after addition of ABDNAZ, and analyzed using FACS. Figure 5 illustrates the percent of apoptosis vs. time in the presence of ABDNAZ. As can be seen in Figures 5, 6 and 7, ABDNAZ induced a very high level of apoptotic cell death in both HL60 neo and bcl-2 cells in a dose-dependent manner. ABDNAZ at 5 μM induced 95% and 78% apoptosis at 48 hours for neo and bcl-2 cells, respectively. At 2 μM , ABDNAZ produced apoptotic cell death that was very similar in HL60 neo and bcl-2 cells with peaks of ~40% at 8 hours.

Figures 6 and 7 illustrates the detailed histograms of FACS analysis for HL60 neo cells and HL60 bcl-2 cells, respectively.

Example 4: Inhibition of bcl-2 Oncogene Expression by ABDNAZ

[00137] HL60 cells were treated as described in Example 2,*supra*. Cells were collected at 6 and 24 hours for Western blot analysis. As shown in Figure 8, ABDNAZ at 2 and 5 uM inhibited bcl-2 protein expression in both neo and bcl-2 cells in a dose-dependent manner. The bcl-2 protein in HL60 bcl-2 transfected cells may be cleaved in the presence of 2uM ABDNAZ as indicated by the presence of the lower molecular weight bands after both 6 and 24 hours.

Example 5: Synthesis of ABDNAZ

[00138] A 25 ml, three-neck, round bottom flask was charged with 7 ml of methylene chloride and 2.50 g (12.3 mmol) of t-BuDNAZ prepared as described in Archibald *et al.*, *Journal of Organic Chemistry*, 1990, 2920. Under nitrogen, 0.16 ml (1.23 mmol) of boron trifluoride etherate was added. After stirring 5 min. at ambient temperature, 0.54 ml (6.15 mol) of bromoacetyl bromide was added. The solution was heated between 50-60°C for 2 h. The darkened reaction mixture was cooled to ambient temperature, diluted with 50 ml methylene chloride, and filtered. The solid was identified as the HBr salt of t-BuDNAZ. The methylene chloride filtrate was washed with two 20 ml portions of water, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The resultant solid was washed with three 20 ml portions of ethyl ether and dried under vacuum to yield 1.24 g (75.2% based on bromoacetyl bromide) of BrADNAZ as a white solid (mp = 124-125°C). ¹H NMR (CDCl₃): δ 3.76 (s, 2H), 4.88 (br s, 2H), 5.14 (br s, 2H); ¹³C NMR (CDCl₃): δ 165.2, 105.0, 59.72, 57.79, 23.90. Calc. for C₅H₆BrN₃O₅: %C 22.41, %H 2.26, %N 15.68; Found: %C 22.61, %H 2.36, %N 15.58. HPLC/MS C-8 reverse phase column with acetonitrile/water mobile phase – m/e 266.95 (100%), 268.95 (98.3%). FT-IR 3014.24 (weak), 1677.66, 1586.30, 1567.65, 1445.55 (NO₂), 1367.80, 1338.00, 1251.27 cm⁻¹.

Example 6: Synthesis of N-(chloroacetyl)-3,3-dinitroazetidine (ClADNAZ)

[00139] A 25 ml, three-neck, round bottom flask was charged with 7 ml of methylene chloride and 2.50 g (12.3 mmol) of t-BuDNAZ. Under nitrogen, 0.16 ml (1.23 mmol) of boron trifluoride etherate was added. After stirring 5 min. at ambient temperature, 0.54 ml (6.15 mol) of chloroacetyl chloride was added. The solution was heated between 50-60°C for 2 h. The darkened reaction mixture was cooled to ambient temperature, diluted with 50 ml methylene chloride and filtered. The solid was identified as the HBr salt of t-BuDNAZ. The methylene chloride filtrate was washed with two 20 ml portions of water, dried over sodium sulfate, filtered, and evaporated under reduced pressure. The resultant solid was washed with three 20 ml portions of ethyl ether and dried under vacuum to afford a white solid (mp: 130-132°C) in 60% yield. CHN for C₅H₆ClN₃O₅: Found C: 26.94%, H: 2.53%, N: 17.77%; Calculated C: 26.86%, H: 2.71% N: 18.79%. FTIR: 2979(weak), 1690.01, 1577.57, 1438.91(NO₂), 1368.21, 1338.99, 1286.21 cm⁻¹. ¹H NMR: (DMSO-d₆), δ 5.09(2H), 4.81(2H), 3.77(2H). ¹³C NMR: (DMSO-d₆), δ 168.58, 106.98, 60.39, 50.38. HPLC: >98% pure. Safety Data: ABI. Impact: 80 cm; ABL Friction: 800@ 8 ft/sec; TC ESD Unconfined at 50%: 1.10 Joules (mass ignition on bulk test). DSC Onset: 259.56°C.

Example 7: Synthesis of N-Iodoacetyl-3,3-dinitroazetidine(IADNAZ)

[00140] A 100 ml, three neck round bottom flask was charged with 40 mL of anhydrous acetone and 2.01 g of BrADNAZ under nitrogen. 1.4 g K₂CO₃ was added followed by the addition of 1.2g sodium iodide. The reaction mixture was allowed to reflux overnight and monitored by proton NMR. The darkened solution was diluted with methylene chloride, the solid was filtered and the filtrate was extracted with 2X 30 mL portions of methylene chloride and water. The organic layer was dried over sodium sulfate and concentrated under vacuum. The solid was purified by flash column chromatography (10% ethyl acetate/hexanes) to yield a white solid (mp 97-100°C) in 80% yield. Analysis for C₅H₆IN₃O₅: Found C: 19.67%, H: 1.80%, N: 12.70%. Calculated C: 19.06%, H: 1.92%, N: 13.24%. FTIR: 2980 (weak), 1667.44, 1568.49, 1439.74 (NO₂), 1373.69, 1335.60, 1305.35 cm⁻¹. ¹H NMR: (DMSO-d₆), δ 5.09(2H), 4.81(2H), 3.77(2H). ¹³C NMR: (DMSO-d₆), δ 168.58, 106.98, 60.39, 50.38. HPLC: >98% pure. Safety Data: ABI. Impact: 80 cm; ABL Friction: 800@ 8 ft/sec; TC ESD,

Unconfined 50% 7.30 Joules(no mass ignition on bulk test); SBAT Onset: 286 °F.
DSC Onset: 253.52 °C.

Example 8: Synthesis of N-Azidoacetyl-3,3-dinitroazetidine(AzADNAZ)

[00141] A 100 ml, three neck flask was charged with 40 mL of anhydrous acetone and 2.01 g of BrADNAZ under nitrogen. 1.05 g K₂CO₃ was added followed by the addition of 0.4g sodium azide. The reaction mixture was allowed to reflux overnight and monitored by proton NMR. The darkened solution was diluted with methylene chloride and the solid was filtered. The filtrate was extracted with 2 30 mL portions of methylene chloride and water. The organic layer was dried over sodium sulfate and concentrated under vacuum. The solid was purified by flash column chromatography (10% Ethyl acetate/Hexanes) to yield a white solid (mp 103-104°C) in 80% yield. Analysis for C₅H₆N₆O₅: Found C: 26.84%, H: 2.70%, N: 35.49%. Calculated C: 26.09%, H: 2.63%, N: 34.76%. FTIR: 2981.60 (weak), 2109.15 (strong), 1678.88, 1598.80, 1571.47, 1463.18 (NO₂), 1446.89, 1332.20, 1275.28 cm⁻¹. ¹H NMR: (DMSO-d₆), δ 5.08(2H), 4.83(2H), 4.02(2H). ¹³C NMR: (DMSO-d₆), δ 169.098, 107.74, 59.84, 58.16. HPLC: >99.7% pure. Safety Data: ABL Impact: 64 cm; ABL Friction: 800@ 8 ft/sec; TC ESD, Unconfined 50% < 0.5 Joules(no mass ignition on bulk test); SBAT Onset: 314 °F.

Example 9: Synthesis of N-Succinyl-3,3-Dinitroazetidine

[00142] A 100 ml, three neck round bottom flask was charged with 30 mL of anhydrous dichloromethane and 5.0 grams of *tert*-butyl-3,3-dinitroazetidine(*t*-BDNAZ) under nitrogen. 4.5 grams of succinyl chloride was added followed by the addition of 0.5 mL of boron trifluoride etherate. The reaction mixture was heated to 50 °C and monitored by NMR. The reaction mixture was poured slowly into ice and then filtered. The brown solid was washed with 3X 20 mL portions of dichloromethane, dried with sodium sulfate and concentrated under vacuum. The solid was purified by flash column chromatography (10% ethyl acetate/hexanes) to yield a pale white solid in 20% yield (mp: 190-192°C). Analysis for C₇H₉N₃O₇: Found C: 33.93%, H: 3.63%, N: 19%. Calculated C: 34.02%; H: 3.67%; N: 17.00. FTIR: 3004.44(weak), 1644.78(strong), 1558.45,

1472.60, 1450.06, 1423.01, 1369.90, 1338.05, 1310.05, 1260.99 cm^{-1} . ^1H NMR: (DMSO- d_6), δ 5.27(2H), 4.85(2H), 2.03(4H). HPLC: >97%. . Safety Data: ABL Impact: 64 cm; ABL Friction: 800@ 8 ft/sec; TC ESD, Unconfined at 50% < 0.26 Joules (no mass ignition at 8 Joules). DSC Onset: 253.86 $^{\circ}\text{C}$.

Example 10: Synthesis of N-Fumaryl-3,3-Dinitroazetidine

[00143] A 100 ml, three neck round bottom flask was charged with 8.69 grams of *tert*-butyl-3,3-dinitroazetidine(*t*-BDNAZ) under nitrogen and 5 mL of fumaryl chloride was added followed by the addition of 0.5 mL of boron trifluoride etherate at 0°C for 2 hours. The reaction mixture was monitored by NMR. The thick paste was washed with methanol and then poured into ice-water. The solid was filtered and washed with 200 mL of water and dried under vacuum which afforded a pale yellow solid in 20% yield (mp: 240°C). Analysis for $\text{C}_7\text{H}_7\text{N}_3\text{O}_7$: Found C: 34.9%, H: 3.2%, N: 19.6%. Calculated C: 34.3%; H: 2.9%; N: 17.1. FTIR: 3082.73(weak), 1664.79(strong), 1577.69, 1430.19 (NO_2), 1366.92, 1274.30, 1231.24, 1213.45 cm^{-1} . ^1H NMR: (DMSO- d_6), δ 5.88(2H), 5.29(2H), 4.90(2H). HPLC:>96%. Safety Data: ABL Friction: 800@ 8 ft/sec. TC ESD Unconfined at 50%: 1.05 Joules (mass ignition on bulk test).

Example 11: Synthesis of N-Trifluoromethyl-3,3-Dinitroazetidine

[00144] A 100 ml, three neck round bottom flask was charged with 2.28 grams of *tert*-butyl-3,3-dinitroazetidine(*t*-BDNAZ) under nitrogen. 10 mL of trifluoroacetic anhydride was added followed by the addition of 0.3 mL of boron trifluoride etherate. The reaction mixture was heated to 50°C and monitored by NMR. The reaction was concentrated under vacuum. The residual oil was washed with water. The residual oil was added to hot hexanes and to afford 460 mg of white needles (mp: $70\text{-}71^{\circ}\text{C}$). Analysis for $\text{C}_5\text{H}_4\text{F}_3\text{N}_3\text{O}_5$: Found C: H: N: Calculated C: 24.70%, H: 1.66%, N: 17.29%. FTIR: 2991 (weak), 1716, 1683.96, 1591.37, 1576.43 (NO_2), 1165.92, 1134.12 cm^{-1} . ^1H NMR: (DMSO- d_6), δ 5.39(2H), 5.04(2H). HPLC: >96% pure. Safety Data: ABL Friction: 800@ 8ft/sec; TC ESD Unconfined at 50%: > 8 Joules. DSC Onset: 240.75°C .s


Example 12

1) Cytotoxicity of ABDNAZ under normoxic and hypoxic condition of SCC VII tumor cells.

Study design: SCC VII squamous cell carcinoma cells were planted in 60-mm glass dishes at a cell density of 500,000 cells per dish in Waymouth's growth medium supplemented with 15% fetal calf serum. ABDNAZ was dissolved in growth medium and added to the dishes at final concentrations of 0-5 μM . Cells were incubated for 2 hours at 37°C in hypoxic jigs (95% nitrogen and 5% air), or in normal oxygen condition (95% air and 5% CO_2). After 2-hour incubation, cells were trypsinized, counted and plated into 60-mm petri dishes in triplicate for colony formation. After 14 days incubation, cells were stained with crystal violet. Colonies containing more than 50 cells were counted and used to calculate surviving fractions.

Results: Figure 1 shows the dose response of SCC VII cells to ABDNAZ under normoxic and hypoxic condition. ABDNAZ inhibited the clonogenic survival of SCC VII cancer cells in a dose-dependent manner under both hypoxic and normoxic conditions. However, cells under hypoxic condition were more sensitive to ABDNAZ than that in normal condition. The IC_{50} (the concentration required for 50% inhibition of colony formation) was 0.093 μM for hypoxic cells and 0.63 μM for normoxic cells, respectively, representing 6.8-times potent under hypoxic condition.

Figure 1. Dose-response of ABDNAZ under hypoxic and normoxic condition.




2) Comparison of cytotoxicity of ABDNAZ and Tirapazimine under hypoxic condition.

Study design: SCC VII carcinoma cells were planted in 60-mm glass dishes at a cell density of 500,000 cells per dish in Waymouth's growth medium supplemented with 15% fetal calf serum. ABDNAZ and tirapazimine was dissolved in growth medium and added to the dishes at final concentrations of 0-5 μ M. Cells were incubated for 2 hours at 37°C in hypoxic jigs (95% nitrogen and 5% air). After 2-hour incubation, cells were trypsinized, counted and plated into 60-mm petri dishes in triplicate and incubated at 37°C for 14 days. Then dishes were stained with crystal violet. Colonies containing more than 50 cells were counted and used to calculate surviving fractions.

Results: As shown in Figure 2 below, both ABDNAZ and tirapazimine inhibited the clonogenic survival in a dose-dependent manner. However, the survival curve of ABDNAZ was shifted downward dramatically compared to the survival curve of tirapazimine, indicating that ABDNAZ is more potent than tirapazimine in inhibiting the clonogenic formation of SCC VII cells under hypoxic condition. At 5 μ M, the survivals were 0.0006 for ABDNAZ and 0.1 for tirapazimine, representing a 2-3 log difference in cell survival.

Figure 2. Cytotoxicity of ABDNAZ and tirapazime under hypoxic condition.




3) Radiosensitization effect of ABDNAZ under hypoxic condition.

Study design: SCC VII cells were planted in 60-mm glass dishes at a cell density of 500,000 cells per dish in Waymouth's growth medium supplemented with 15% fetal calf serum. ABDNAZ was added to the dishes at a final concentrations of 1 μ M. Cells were immediately irradiated in hypoxic jigs (95% nitrogen and 5% air) with 0-10 Gy using a ^{137}Cs source with a dose rate of 3 Gy/min. Two hours after radiation, cells were trypsinized, counted and plated into 60-mm petri dishes in triplicate for colony formation. After 14 days incubation, dishes were stained with crystal violet. Colonies containing more than 50 cells were counted and used to calculate surviving fractions.

Results: Figure 3 shows the radiation dose-response survival curves of SCC VII cells with or without ABDNAZ. Radiation alone reduced the survival in a dose-dependent manner. When combined with ABDNAZ, the survival curves decreased significantly. A dose of 1.0 μ M ABDNAZ decreased the clonogenic survival by 1 logs at 10Gy.

Figure 3. ABDNAZ radiosensitizes SCC VII cells under hypoxia.




4) Anti-tumor efficacy of ABDNAZ and cisplatin in SCC VII tumor model in mice.

Study design: Mice were subcutaneously implanted in the right flank with 500,000 SCC VII tumor cells in a suspension volume of 50 μ L. One tumor per mouse was implanted. When tumors reached an average size of 100 mm^3 (80-150 mm^3).

animals were treated intraperitoneally with a single dose of ABDNAZ (15mg/kg body weight) or cisplatin (10mg/kg). Six to 8 mice were used in each group. The length, width and height of the tumors were measured with calipers before treatment and three times a week thereafter until the tumor volume reached at least four times (4x) the original pretreatment volume. Tumor volume (in mm³) was calculated according to the formula: tumor volume = $\pi/6 \times \text{length} \times \text{width} \times \text{height}$. Data are expressed as the relative tumor volume to the pretreatment volume on Day 0 and as the mean tumor growth delay time. The tumor growth delay time is the difference between the 4x time of treated tumors compared to that of untreated control tumors. This was calculated for each individual animal treated, and then averaged for each group.

Results: As shown in Figure 4 below, ABDNAZ at a single dose of 15mg/kg and cisplatin at a single dose of 10mg/kg inhibited the tumor growth and produced a 4x tumor growth delay time of 4.5 ± 1.1 and 4.3 ± 0.9 days, respectively. There was no statistically significant differences in tumor growth delay time between ABDNAZ and cisplatin- treated tumors ($P = 0.7$).

Figure 4. Anti-tumor efficacy of ABDNAZ and cisplatin in tumor-bearing mice.




1) Toxicity of ABDNAZ and cisplatin in mice bearing SCC VII tumors.

Mice were subcutaneously implanted in the right flank with 500,000 SCC VII tumor cells. One tumor per mouse was implanted. When tumors reached an average size of 100 mm³ (80-150 mm³), animals were treated intraperitoneally with ABDNAZ (10mg/kg body weight, 3 dose in one week, or 5mg/kg 5 doses in one week) or

cisplatin (10mg/kg single dose). Six to 8 mice were used in each group. Body weight of the tumor-bearing mice was measured three times weekly. Data are expressed as the relative body weight to the pretreatment weight measured on Day 0.

As shown in Figure below, ABDNAZ at an accumulated dose of 25-30 mg/kg did not decrease the body weight compared to that of untreated control mice. However, cisplatin at a single dose of 10mg/kg caused a decrease in body weight, e.g. a 13% decrease on day 5 after administration of cisplatin compared to untreated control mice.

Figure. Body weight of tumor-bearing mice treated with ABDNAZ and cisplatin.




[00145] Finally, it should be noted that there are alternative ways of implementing the present invention. Accordingly, the present embodiments are to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims. All publications and patents cited herein are incorporated by reference.

[00146] All references and publications cited herein are incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. A compound of structural Formula (I):



or salts, solvates or hydrates thereof wherein:

R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

each R^5 and R^6 are each independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halo, hydroxy or nitro;

α is 0, 1, 2, 3 or 4;

R^7 is substituted alkyl, substituted arylalkyl, substituted heteroalkyl, substituted heteroaryl, substituted heteroarylalkyl, substituted acyl, substituted alkoxycarbonyl, substituted phosphonyl or substituted sulfonyl;

provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are nitro.

2. The compound of Claim 1 in which at least two of R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are nitro.

3. The compound of Claim 1 in which R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro and each R^5 and R^6 are each independently, hydrogen, alkyl or nitro.

4. The compound of Claim 1 in which R^7 is substituted alkyl, substituted acyl, substituted alkoxy carbonyl, substituted phosphonyl or substituted sulfonyl.

5. The compound of Claim 1 in which R^7 is alkyl, acyl, alkoxy carbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl.

6. The compound of Claim 1 in which R^3 and R^4 are nitro.

7. The compound of Claim 1 in which R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is substituted alkyl, substituted acyl, substituted alkoxy carbonyl, substituted phosphonyl or substituted sulfonyl.

8. The compound of Claim 1 in which R^1 , R^2 , R^3 and R^4 are each independently, hydrogen, alkyl or nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is alkyl, acyl, alkoxy carbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl.

9. The compound of Claim 1 in which R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is substituted alkyl, substituted acyl, substituted alkoxy carbonyl, substituted phosphonyl or substituted sulfonyl.


10. The compound of Claim 1 in which R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is alkyl, acyl, alkoxy carbonyl, phosphonyl or sulfonyl substituted with one or more halogen, $-CF_3$ or $-OS(O)_2R^8$ wherein R^8 is alkyl, substituted alkyl, aryl or substituted aryl.

11. The compound of any of Claims 1-10 in which o is 1.

12. The compound of Claim 1 in which R^1 and R^2 are each independently, hydrogen, alkyl or nitro, R^3 and R^4 are nitro, each R^5 and R^6 are each independently, hydrogen, alkyl or nitro and R^7 is alkyl or acyl substituted with one or more halogen or $-CF_3$ and o is 1.


13. The compound of Claim 1 in which R^1 and R^2 are hydrogen, R^3 and R^4 are nitro, R^5 and R^6 are hydrogen, R^7 is alkyl or acyl substituted with one or more halogen or $-\text{CF}_3$ and o is 1.

14. The compound of Claim 1 having the structure:



wherein each X is independently -F, -Cl, -Br, -I or $-\text{OS}(\text{O})_2\text{R}^8$ where R^8 is methyl, CF_3 , phenyl or tolyl and each p is independently 1, 2, 3, or 4.

15. The compound of Claim 1 having the structure:



wherein each X is independently -F, -Cl, -Br, -I or $-\text{OS}(\text{O})_2\text{R}^8$ where R^8 is methyl, CF_3 , phenyl or tolyl.

16. A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable vehicle.

17. A method for treating or preventing cancer in a patient comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the compound of Claim 1.

18. The method of any one of Claims 16 or 17 in which the cancer is breast cancer, renal cancer, brain cancer, colon cancer, colorectal cancer, prostate cancer or lung cancer.

19. A method for treating tumor cells with a reduced intracellular environment in a patient, comprising administering to the patient in need of treatment a therapeutically effective amount of the compound of Claim 1.

20. A method for treating or preventing solid tumors in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of the compound of Claim 1.

21. A method for treating or preventing leukemias and lymphomas in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of the compound of Claim 1.

22. A method for treating or preventing inflammation in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of the compound of Claim 1.

23. A method for treating or preventing autoimmune disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of the compound of Claim 1.

24. A method for treating or preventing cardiovascular disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of the compound of Claim 1.

ABSTRACT OF THE INVENTION

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

1-SF/7505166.1




Figure 1




Figure 2





Figure 3

HL60 vector cells



HL60 bcl-2 cells




Figure 4




Figure 5




Figure 6




Figure 7

ABDNAZ (uM)	bcl-2		neo	
	6 hrs		6 hrs	
	2	5	2	5
	2	5	2	5
	0	0	0	0
	2	5	2	5
	2	5	2	5

bcl-2 →




Figure 8